Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AngioDynamics (ANGO)
NASDAQ:ANGO
Holding ANGO?
Track your performance easily
Earnings Data
Report Date
Jan 08, 2025Before Open Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-$0.11Last Year’s EPS
-$0.05Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 03, 2024
|% Change Since: 16.21%
|Next Earnings Date:Jan 08, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced picture with strong growth in the Med Tech segment, particularly from Auryon and AlphaVac, and progress towards profitability. However, challenges remain in the Med Device segment and cash utilization was significant.Company Guidance
During the AngioDynamics fiscal year 2025 first quarter earnings call, the company provided guidance for the balance of the year, maintaining their revenue expectations in the range of $282 million to $288 million, reflecting growth of 4.2% to 6.4% over the previous year. The Med Tech segment is anticipated to grow by 10% to 12%, while the Med Device segment is expected to see a 1% to 3% increase. Gross margin is projected to be between 52% and 53%, with adjusted EBITDA ranging from a loss of $2.5 million to breakeven. The adjusted loss per share is expected to be between $0.38 and $0.42. The company highlighted key catalysts, including product launches, regulatory approvals, and geographic expansions, supporting their strategic growth initiatives.Med Tech Segment Growth
The Med Tech segment grew approximately 9%, led by Auryon and AlphaVac, which both grew over 20%.
CE Mark Approval for Auryon
Received CE mark approval for Auryon, allowing access to the European PAD market.
Strong AlphaVac Performance
AlphaVac revenue increased by over 21%, highlighting strong demand for its use in treating PE.
Profitability Progress
Reported an adjusted EBITDA loss of just $200,000, improving from a $1.1 million loss in fiscal 2024.
NanoKnife Adoption
Despite a revenue decline, there is a steady increase in prostate case volumes with NanoKnife, and completed a 12-month follow-up in the PRESERVE study.
---
ANGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 03, 2024 | $7.65 | $6.37 | -16.73% |
| Jul 16, 2024 | $5.93 | $7.51 | +26.64% |
| Apr 04, 2024 | $6.08 | $6.40 | +5.26% |
| Jan 05, 2024 | $7.75 | $6.21 | -19.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AngioDynamics (ANGO) report earnings?
AngioDynamics (ANGO) is schdueled to report earning on Jan 08, 2025, Before Open Not Confirmed.
What is AngioDynamics (ANGO) earnings time?
AngioDynamics (ANGO) earnings time is at Jan 08, 2025, Before Open Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANGO EPS forecast?
ANGO EPS forecast for the fiscal quarter 2025 (Q2) is -$0.11.
---
